Individuals with depression, on common, die prematurely, have excessive ranges of bodily comorbidities and might expertise accelerated organic ageing. A larger understanding of age-related changes in physiology might present novel organic insights that will assist inform methods to mitigate extra mortality in depression. We used generalised additive fashions to look at age-related changes in 15 cardiovascular, body composition, grip strength and lung operate measures, evaluating males and females with a lifetime historical past of depression to wholesome controls.
The important dataset included 342,393 adults (imply age = 55.87 years, SD = 8.09; 52.61% females). We discovered statistically important case-control variations for many physiological measures. There was some proof that age-related changes in body composition, cardiovascular operate, lung operate and heel bone mineral density adopted totally different trajectories in depression.
These variations didn’t uniformly slender or widen with age and differed by intercourse. For instance, BMI in feminine instances was 1.1 kg/m2 larger at age 40 and this distinction narrowed to 0.four kg/m2 at age 70. In males, systolic blood strain was 1 mmHg decrease in depression instances at age 45 and this distinction widened to 2.5 mmHg at age 65. These findings counsel that focused screening for physiological operate in middle-aged and older adults with depression is warranted to probably mitigate extra mortality.
Can an information pushed weight problems classification system establish these susceptible to extreme COVID-19 in the UK Biobank cohort research?
COVID-19 is a illness that has been proven to have outcomes that fluctuate by sure socio-demographic and socio-economic teams. It is more and more vital that an understanding of those outcomes ought to be derived not from the consideration of 1 facet, however by a extra multi-faceted understanding of the particular person. In this research use is fabricated from a latest weight problems pushed classification of contributors in the United Kingdom Biobank (UKB) to establish traits in COVID-19 outcomes.
This classification is knowledgeable by a lately created weight problems methods map, and the COVID-19 outcomes are: endeavor a take a look at, a optimistic take a look at, hospitalisation and mortality. It is demonstrated that the classification is ready to establish significant differentials in these outcomes. This extra holistic strategy is advisable for identification and prioritisation of COVID-19 threat and attainable long-COVID willpower.
Whole-exome imputation inside UK Biobank powers uncommon coding variant affiliation and fine-mapping analyses
Exome affiliation research thus far have typically been underpowered to systematically consider the phenotypic affect of very uncommon coding variants. We leveraged in depth haplotype sharing between 49,960 exome-sequenced UK Biobank contributors and the the rest of the cohort (complete n ≈ 500,000) to impute exome-wide variants with accuracy R2 > 0.5 all the way down to minor allele frequency (MAF) ~0.00005.
Association and fine-mapping analyses of 54 quantitative traits recognized 1,189 important associations (P < 5 × 10-8) involving 675 distinct uncommon protein-altering variants (MAF < 0.01) that handed stringent filters for seemingly causality.
Across all traits, 49% of associations (578/1,189) occurred in genes with two or extra hits; follow-up analyses of those genes recognized allelic collection containing as much as 45 distinct ‘likely-causal’ variants. Our outcomes exhibit the utility of within-cohort imputation in population-scale genome-wide affiliation research, present a catalog of likely-causal, large-effect coding variant associations and foreshadow the insights that shall be revealed as genetic biobank research proceed to develop.
The governance of genomic biobank analysis in Africa: reframing the regulatory tilt
Genomic biobank analysis has skilled exponential progress in latest years. It represents an actual alternative to treatment international well being inequity that has seen restricted funding in ailments affecting populations from low- and middle-income international locations. Previous analysis in Africa was restricted to so-called parachute analysis, whereby samples had been taken from native populations to be used in high-income international locations with no native oversight or use of the pattern.
These exploitative practices have to be guarded towards, however the present regulation of genomic analysis in Africa adopts a precautionary strategy that at instances is restrictive in nature. We argue that the regulation and oversight of genomic biobank analysis ought to guard towards exploitative analysis, however in a fashion that promotes reciprocal profit and not restrictive analysis practices. To obtain this, there have to be a rebalancing of the regulatory tilt.
The biobank of barretos most cancers hospital: 14 years of expertise in most cancers analysis
Despite the developments in most cancers analysis over years, most cancers remains to be considered one of the main causes of loss of life worldwide. In Brazil, the variety of most cancers instances for the a number of subsequent years (2020-2022) is predicted to extend as much as 625,000. Thus, translational analysis has been important to find out the potential threat, prognostic, and predictive biomarkers in most cancers. Therefore, Barretos Cancer Hospital applied a biobank (BB-BCH) in 2006, which is liable for processing, storage, and provision of organic supplies from most cancers and non-cancer contributors.
Hence, this text aimed to explain BB-BCH’s historical past, experiences, and outcomes and discover its affect on Brazilian translational oncology analysis state of affairs. BB-BCH has a multidisciplinary group who’re liable for guaranteeing the high quality of all processes as advisable by worldwide pointers for biobanks. Furthermore, BB-BCH has ample gear to make sure the high quality of all materials requested by researchers as genetic materials (DNA and RNA) and/or total biospecimens.
 ELISA Kit) Human Transforming growth factor beta 1 (TGF-b1) ELISA Kit |
|||
| LF-EK60028 | Abfrontier | 1×96T | EUR 790 |
 CLIA Kit) Human Transforming Growth Factor Beta 1 (TGF-b1) CLIA Kit |
|||
| abx196293-96tests | Abbexa | 96 tests | EUR 825 |
 TGF |
|||
| EF000223 | Lifescience Market | 96 Tests | EUR 689 |
TGF |
|||
| EF000225 | Lifescience Market | 96 Tests | EUR 689 |
TGF |
|||
| EF000226 | Lifescience Market | 96 Tests | EUR 689 |
TGF |
|||
| EF000227 | Lifescience Market | 96 Tests | EUR 689 |
TGF |
|||
| EF016747 | Lifescience Market | 96 Tests | EUR 689 |
 TGF- |
|||
| EF016878 | Lifescience Market | 96 Tests | EUR 689 |
TGF- |
|||
| EF017053 | Lifescience Market | 96 Tests | EUR 689 |
TGF- |
|||
| EF017054 | Lifescience Market | 96 Tests | EUR 689 |
TGF- |
|||
| EF017076 | Lifescience Market | 96 Tests | EUR 689 |
TGF- |
|||
| EF018074 | Lifescience Market | 96 Tests | EUR 689 |
TGF- |
|||
| EF019518 | Lifescience Market | 96 Tests | EUR 689 |
TGF- |
|||
| EF016694 | Lifescience Market | 96 Tests | EUR 689 |
TGF- |
|||
| EF010976 | Lifescience Market | 96 Tests | EUR 689 |
TGF- |
|||
| EF012749 | Lifescience Market | 96 Tests | EUR 689 |
TGF- |
|||
| EF012916 | Lifescience Market | 96 Tests | EUR 689 |
TGF- |
|||
| EF012917 | Lifescience Market | 96 Tests | EUR 689 |
TGF- |
|||
| EF012918 | Lifescience Market | 96 Tests | EUR 689 |
TGF |
|||
| ABF5347 | Lifescience Market | 100 ug | EUR 438 |
TGF |
|||
| ABF8080 | Lifescience Market | 100 ug | EUR 438 |
TGF |
|||
| ABF8081 | Lifescience Market | 100 ug | EUR 438 |
TGF |
|||
| ABD8749 | Lifescience Market | 100 ug | EUR 438 |
 Antibody) Protein B1 (B1) Antibody |
|||
| 20-abx317795 | Abbexa |
|
|
 TGF beta |
|||
| MO20012 | Neuromics | 100 ul. | EUR 246 |
 TGF Beta1 |
|||
| PR15009 | Neuromics | 1 ug | EUR 376 |
TGF Beta1 |
|||
| PR27106 | Neuromics | 2 ug | EUR 257 |
 TGF Beta3 |
|||
| PR27164 | Neuromics | 2 ug | EUR 191 |
 TGF Beta2 |
|||
| PR27165 | Neuromics | 5 ug | EUR 318 |
 TGF-beta3 |
|||
| GT15074 | Neuromics | 100 ug | EUR 526 |
 Antibody (HRP)) Protein B1 (B1) Antibody (HRP) |
|||
| 20-abx317796 | Abbexa |
|
|
 Antibody (FITC)) Protein B1 (B1) Antibody (FITC) |
|||
| 20-abx317797 | Abbexa |
|
|
 Antibody (Biotin)) Protein B1 (B1) Antibody (Biotin) |
|||
| 20-abx317798 | Abbexa |
|
|
 Antibody) Ephrin B1 (Ephrin B1) Antibody |
|||
| abx232810-100ug | Abbexa | 100 ug | EUR 481 |
 TGF-Alpha/ Rat TGF- Alpha ELISA Kit |
|||
| ELA-E0123r | Lifescience Market | 96 Tests | EUR 886 |
 TGF-Beta1/ Rat TGF- Beta1 ELISA Kit |
|||
| ELA-E0124r | Lifescience Market | 96 Tests | EUR 886 |
 TGF-Beta/ Rat TGF- Beta ELISA Kit |
|||
| ELA-E1949r | Lifescience Market | 96 Tests | EUR 886 |
 Bovine Insulin ELISA Kit, 96 tests, Quantitative, 96 tests |
|||
| 0030-10-B1 | Alpha Diagnostics | 1 kit | EUR 651 |
 Procyanidin B1 |
|||
| TB0698 | ChemNorm | 10mg | EUR 249 |
 Jionoside B1 |
|||
| TB0813-0025 | ChemNorm | 10mg | EUR 484 |
 Ilexsaponin B1 |
|||
| TBW00086 | ChemNorm | 10mg | EUR 420 |
 Aflatoxin B1 |
|||
| TBW00290 | ChemNorm | 1ml | EUR 313 |
 Enniatin B1 |
|||
| TBW01226 | ChemNorm | unit | Ask for price |
 Cinnamtannin B1 |
|||
| TBW01547 | ChemNorm | unit | Ask for price |
 Cylindrol B1 |
|||
| TBZ0224 | ChemNorm | unit | Ask for price |
 Jujuboside B1 |
|||
| TBZ2572 | ChemNorm | 10mg | Ask for price |
 Saikosaponin B1 |
|||
| TS054284 | ChemNorm | 20mg | Ask for price |
 Tacacoside B1 |
|||
| TBZ0924 | ChemNorm | unit | Ask for price |
 Yunganoside B1 |
|||
| TBZ1059 | ChemNorm | unit | Ask for price |
 Combretastatin B1 |
|||
| TBZ1177 | ChemNorm | unit | Ask for price |
 Meliatoxin B1 |
|||
| TBZ1616 | ChemNorm | unit | Ask for price |
 Prostaglandin B1 |
|||
| TBZ1840 | ChemNorm | unit | Ask for price |
 B1 Antibody |
|||
| 1-CSB-PA882501LA01HKA | Cusabio |
|
|
|
Description: A polyclonal antibody against B1. Recognizes B1 from Human herpesvirus 6B. This antibody is Unconjugated. Tested in the following application: ELISA, WB; Recommended dilution: WB:1:500-1:5000 |
|||
 Bafilomycin B1 |
|||
| B039-1MG | TOKU-E | 1 mg | EUR 157 |
Bafilomycin B1 |
|||
| B039-5MG | TOKU-E | 5 mg | EUR 473 |
 Fumonisin B1 |
|||
| 20-abx076560 | Abbexa |
|
|
Aflatoxin B1 |
|||
| A115-1MG | TOKU-E | 1 mg | EUR 119 |
Aflatoxin B1 |
|||
| A115-5MG | TOKU-E | 5 mg | EUR 342 |
Bafilomycin B1 |
|||
| GA8347-100UG | Glentham Life Sciences | 100 ug | EUR 114 |
Bafilomycin B1 |
|||
| GA8347-1MG | Glentham Life Sciences | 1 mg | EUR 166 |
Bafilomycin B1 |
|||
| GA8347-5MG | Glentham Life Sciences | 5 mg | EUR 355 |
 Ephrin B1 |
|||
| PR27094 | Neuromics | 5 ug | EUR 191 |
 Saquayamycin B1 |
|||
| GL5222-1MG | Glentham Life Sciences | 1 mg | EUR 229 |
Saquayamycin B1 |
|||
| GL5222-500UG | Glentham Life Sciences | 500 ug | EUR 172 |
Saquayamycin B1 |
|||
| GL5222-5MG | Glentham Life Sciences | 5 mg | EUR 551 |
 Avermectin B1 |
|||
| HY-15311 | MedChemExpress | 100mg | EUR 121 |
Fumonisin B1 |
|||
| F030-0.5MG | TOKU-E | 0.5 mg | EUR 154 |
Fumonisin B1 |
|||
| F030-2.5MG | TOKU-E | 2.5 mg | EUR 465 |
 Nafocare B1 |
|||
| HY-100241 | MedChemExpress | 10mg | EUR 3730 |
Saikosaponin B1 |
|||
| HY-N0247 | MedChemExpress | 10mg | EUR 398 |
Procyanidin B1 |
|||
| HY-N0795 | MedChemExpress | 10mg | EUR 1359 |
Jionoside B1 |
|||
| HY-N2218 | MedChemExpress | 5mg | EUR 509 |
Aflatoxin B1 |
|||
| HY-N6615 | MedChemExpress | 10mM/1mL | EUR 311 |
Fumonisin B1 |
|||
| HY-N6719 | MedChemExpress | 1mg | EUR 302 |
) Coxsackievirus (B1) |
|||
| DAG4690 | Creative Diagnostics | 0.25 mg | Ask for price |
Enniatin B1 |
|||
| E038-1MG | TOKU-E | 1 mg | EUR 224 |
Enniatin B1 |
|||
| E038-5MG | TOKU-E | 5 mg | EUR 708 |
Fumonisin B1 |
|||
| A4537-1 | ApexBio | 1 mg | EUR 132 |
|
Description: Mycotoxin produced by Fusarium moniliforme. Potently inhibits sphingosine N-acyltransferase (ceramide synthase), causing an accumulation of sphingoid bases (IC50 ~ 75 nM). |
|||
Fumonisin B1 |
|||
| A4537-10 | ApexBio | 10 mg | EUR 666 |
|
Description: Mycotoxin produced by Fusarium moniliforme. Potently inhibits sphingosine N-acyltransferase (ceramide synthase), causing an accumulation of sphingoid bases (IC50 ~ 75 nM). |
|||
Fumonisin B1 |
|||
| A4537-5 | ApexBio | 5 mg | EUR 419 |
|
Description: Mycotoxin produced by Fusarium moniliforme. Potently inhibits sphingosine N-acyltransferase (ceramide synthase), causing an accumulation of sphingoid bases (IC50 ~ 75 nM). |
|||
Avermectin B1 |
|||
| A3202-100 | ApexBio | 100 mg | EUR 112 |
|
Description: Avermectin B1 (Abamectin) is a widely used insecticide and anthelmintic. Avermectin B1 is a mixture of avermectins containing more than 80% avermectin B1a and less than 20% avermectin B1b. |
|||
Avermectin B1 |
|||
| A3202-1000 | ApexBio | 1 g | EUR 144 |
|
Description: Avermectin B1 (Abamectin) is a widely used insecticide and anthelmintic. Avermectin B1 is a mixture of avermectins containing more than 80% avermectin B1a and less than 20% avermectin B1b. |
|||
Avermectin B1 |
|||
| A3202-10000 | ApexBio | 10 g | EUR 676 |
|
Description: Avermectin B1 (Abamectin) is a widely used insecticide and anthelmintic. Avermectin B1 is a mixture of avermectins containing more than 80% avermectin B1a and less than 20% avermectin B1b. |
|||
Avermectin B1 |
|||
| A3202-5000 | ApexBio | 5 g | EUR 395 |
|
Description: Avermectin B1 (Abamectin) is a widely used insecticide and anthelmintic. Avermectin B1 is a mixture of avermectins containing more than 80% avermectin B1a and less than 20% avermectin B1b. |
|||
 Polymyxin B1 |
|||
| C3598-1 | ApexBio | 1 mg | EUR 186 |
|
Description: Polymyxin B1 can bind and kill Gram-negative bacteria.In view of the emergence of multidrug resistance among Gram-negative bacteria, polymyxin B has emerged as one of the therapeutic agents of last resort. |
|||
Polymyxin B1 |
|||
| C3598-10 | ApexBio | 10 mg | EUR 920 |
|
Description: Polymyxin B1 can bind and kill Gram-negative bacteria.In view of the emergence of multidrug resistance among Gram-negative bacteria, polymyxin B has emerged as one of the therapeutic agents of last resort. |
|||
Polymyxin B1 |
|||
| C3598-5 | ApexBio | 5 mg | EUR 595 |
|
Description: Polymyxin B1 can bind and kill Gram-negative bacteria.In view of the emergence of multidrug resistance among Gram-negative bacteria, polymyxin B has emerged as one of the therapeutic agents of last resort. |
|||
 Demethylasterriquinone B1 |
|||
| B6869-1 | ApexBio | 1 mg | EUR 126 |
Demethylasterriquinone B1 |
|||
| B6869-5 | ApexBio | 5 mg | EUR 348 |
 Proanthocyanidin B1 |
|||
| N2180-5 | ApexBio | 5 mg | EUR 572 |
|
Description: Extracted from Betula pubescens Ehrh. hypophloedes;Store the product in sealed, cool and dry condition |
|||
 TGF alpha antibody |
|||
| 70R-50472 | Fitzgerald | 100 ul | EUR 244 |
|
Description: Purified Polyclonal TGF alpha antibody |
|||
TGF alpha antibody |
|||
| 70R-51342 | Fitzgerald | 100 ul | EUR 244 |
|
Description: Purified Polyclonal TGF alpha antibody |
|||
 TGF beta2 Antibody |
|||
| AF0260 | Affbiotech | 200ul | EUR 304 |
|
Description: TGF beta2 Antibody detects endogenous levels of TGF beta2. |
|||
 TGF alpha Antibody |
|||
| AF0262 | Affbiotech | 200ul | EUR 304 |
|
Description: TGF alpha antibody detects endogenous levels of total TGF alpha. |
|||
 TGF beta1 Antibody |
|||
| AF1027 | Affbiotech | 200ul | EUR 304 |
|
Description: TGF beta1 Antibody detects endogenous levels of total TGF beta protein. |
|||
TGF beta1 Antibody |
|||
| BF0173 | Affbiotech | 200ul | EUR 376 |
|
Description: TGF beta1 antibody detects endogenous levels of total TGF beta1. |
|||
TGF beta2 Antibody |
|||
| ABF0260 | Lifescience Market | 100 ug | EUR 438 |
TGF alpha Antibody |
|||
| ABF0262 | Lifescience Market | 100 ug | EUR 438 |
TGF beta1 Antibody |
|||
| ABF1027 | Lifescience Market | 100 ug | EUR 438 |
 anti-TGF alpha |
|||
| YF-PA15003 | Abfrontier | 100 ug | EUR 403 |
|
Description: Rabbit polyclonal to TGF alpha |
|||
anti-TGF alpha |
|||
| YF-PA24840 | Abfrontier | 50 ul | EUR 334 |
|
Description: Mouse polyclonal to TGF alpha |
|||
 TGF alpha protein |
|||
| 30R-2357 | Fitzgerald | 20 ug | EUR 224 |
|
Description: Purified recombinant Human TGF alpha protein |
|||
TGF alpha antibody |
|||
| 20C-CR2026SP | Fitzgerald | 2.5 mg | EUR 374 |
|
Description: Sheep polyclonal TGF alpha antibody |
|||
TGF alpha protein |
|||
| 30R-AT002 | Fitzgerald | 20 ug | EUR 133 |
|
Description: Purified recombinant Human TGF alpha protein |
|||
TGF alpha antibody |
|||
| 70R-12318 | Fitzgerald | 100 ug | EUR 403 |
|
Description: Rabbit polyclonal TGF alpha antibody |
|||
 TGF beta antibody |
|||
| 70R-12368 | Fitzgerald | 100 ug | EUR 527 |
|
Description: Rabbit polyclonal TGF beta antibody |
|||
TGF alpha antibody |
|||
| 70-TG89 | Fitzgerald | 1 mg | EUR 812 |
|
Description: Affinity purified Goat polyclonal TGF alpha antibody |
|||
TGF beta antibody |
|||
| 70-TG90 | Fitzgerald | 1 mg | EUR 789 |
|
Description: Affinity purified Goat polyclonal TGF beta antibody |
|||
TGF alpha antibody |
|||
| 70-TR56 | Fitzgerald | 50 ug | EUR 298 |
|
Description: Affinity purified Rabbit polyclonal TGF alpha antibody |
|||
TGF alpha antibody |
|||
| 70R-30774 | Fitzgerald | 100 ug | EUR 327 |
|
Description: Rabbit polyclonal TGF alpha antibody |
|||
TGF alpha antibody |
|||
| 70R-13903 | Fitzgerald | 100 ug | EUR 322 |
|
Description: Affinity purified Sheep polyclonal TGF alpha antibody |
|||
TGF alpha antibody |
|||
| 70R-15427 | Fitzgerald | 100 ug | EUR 327 |
|
Description: Rabbit polyclonal TGF alpha antibody |
|||
TGF alpha antibody |
|||
| 10R-T120a | Fitzgerald | 100 ug | EUR 500 |
|
Description: Mouse monoclonal TGF alpha antibody |
|||
TGF beta antibody |
|||
| 10R-6686 | Fitzgerald | 50 ug | EUR 181 |
|
Description: Rat monoclonal TGF beta antibody |
|||
TGF beta antibody |
|||
| 10R-7765 | Fitzgerald | 500 ug | EUR 565 |
|
Description: Mouse monoclonal TGF beta antibody |
|||
 TGF-alpha Antibody |
|||
| 5339-100 | Biovision | EUR 316 | |
TGF-alpha Antibody |
|||
| 5339-30T | Biovision | EUR 146 | |
 TGF-beta2 Antibody |
|||
| 5340-100 | Biovision | EUR 316 | |
TGF-beta2 Antibody |
|||
| 5340-30T | Biovision | EUR 146 | |
TGF-beta2 Antibody |
|||
| 5343R-100 | Biovision | EUR 316 | |
TGF-beta2 Antibody |
|||
| 5343R-30T | Biovision | EUR 146 | |
 TGF-beta3 Antibody |
|||
| 5344R-100 | Biovision | EUR 316 | |
TGF-beta3 Antibody |
|||
| 5344R-30T | Biovision | EUR 146 | |
 TGF-?1 Antibody |
|||
| 5559-100 | Biovision | EUR 403 | |
TGF-?1 Antibody |
|||
| 5559-30T | Biovision | EUR 164 | |
 pET-28a-TGF |
|||
| PVTB00118-1a | Lifescience Market | 2 ug | EUR 356 |
 Pro-TGF-a |
|||
| 5-01812 | CHI Scientific | 4 x 5mg | Ask for price |
 Human TGF-β3 |
|||
| BJU020 | GroPep | 20 µg | EUR 253 |
Human TGF-β3 |
|||
| BJU100 | GroPep | 100 µg | EUR 346 |
 TGF-alpha, CF |
|||
| PR15016CF | Neuromics | 500 ug | EUR 1342 |
 TGF-b Antibody |
|||
| 21678-100ul | SAB | 100ul | EUR 252 |
TGF-b Antibody |
|||
| 21678-50ul | SAB | 50ul | EUR 187 |
 TGF β2 Antibody |
|||
| 33497-100ul | SAB | 100ul | EUR 252 |
TGF β2 Antibody |
|||
| 33497-50ul | SAB | 50ul | EUR 187 |
 TGF β3 Antibody |
|||
| 33498-100ul | SAB | 100ul | EUR 252 |
TGF β3 Antibody |
|||
| 33498-50ul | SAB | 50ul | EUR 187 |
TGF alpha Antibody |
|||
| 33499-100ul | SAB | 100ul | EUR 252 |
TGF alpha Antibody |
|||
| 33499-50ul | SAB | 50ul | EUR 187 |
TGF alpha Antibody |
|||
| 49822-100ul | SAB | 100ul | EUR 333 |
TGF alpha Antibody |
|||
| 49822-50ul | SAB | 50ul | EUR 239 |
 TGF? Polyclonal Antibody |
|||
| ES8382-100ul | ELK Biotech | 100ul | EUR 279 |
|
Description: A Rabbit Polyclonal antibody against TGF? from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA |
|||
TGF? Polyclonal Antibody |
|||
| ES8382-50ul | ELK Biotech | 50ul | EUR 207 |
|
Description: A Rabbit Polyclonal antibody against TGF? from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA |
|||
 TGF-beta1, Human |
|||
| HY-P7118 | MedChemExpress | 100ug | EUR 1221 |
 TGF-beta2, Human |
|||
| HY-P7119 | MedChemExpress | 50ug | EUR 957 |
 TGF-α, Human |
|||
| HY-P7411 | MedChemExpress | 50ug | EUR 234 |
TGF? Polyclonal Antibody |
|||
| ES3593-50ul | ELK Biotech | 50ul | EUR 207 |
|
Description: A Rabbit Polyclonal antibody against TGF? from Human/Mouse/Rat/Monkey. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA |
|||
TGF? Polyclonal Antibody |
|||
| ES3593-100ul | ELK Biotech | 100ul | EUR 279 |
|
Description: A Rabbit Polyclonal antibody against TGF? from Human/Mouse/Rat/Monkey. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA |
|||
 antibody) TGF-? (Human) antibody |
|||
| Y240 | Sceti | 50 ul | EUR 427 |
|
Description: The TGF-? (Human) antibody is available in Europe and for worldwide shipping via Gentaur. |
|||
) Goat(TGF-β) |
|||
| QY-E140043 | Qayee Biotechnology | 96T | EUR 413 |
 TGF-尾 ELISA KIT|Mouse TGF-尾 ELISA KIT |
|||
| EF013931 | Lifescience Market | 96 Tests | EUR 689 |
 Cyclin B1 antibody |
|||
| 70R-36736 | Fitzgerald | 100 ug | EUR 327 |
|
Description: Rabbit Polyclonal Cyclin B1 antibody |
|||
Cyclin B1 antibody |
|||
| 70R-49488 | Fitzgerald | 100 ul | EUR 287 |
|
Description: Purified Polyclonal Cyclin B1 antibody |
|||
Cyclin B1 antibody |
|||
| 70R-49489 | Fitzgerald | 100 ul | EUR 244 |
|
Description: Purified Polyclonal Cyclin B1 antibody |
|||
 Ephrin B1 antibody |
|||
| 70R-49688 | Fitzgerald | 100 ul | EUR 287 |
|
Description: Purified Polyclonal Ephrin B1 antibody |
|||
 Lamin B1 antibody |
|||
| 70R-50012 | Fitzgerald | 100 ul | EUR 244 |
|
Description: Purified Polyclonal Lamin B1 antibody |
|||
 Chymotrypsinogen B1 antibody |
|||
| 70R-7495 | Fitzgerald | 50 ug | EUR 467 |
|
Description: Rabbit polyclonal Chymotrypsinogen B1 antibody raised against the middle region of CTRB1 |
|||
Chymotrypsinogen B1 antibody |
|||
| 70R-7498 | Fitzgerald | 50 ug | EUR 467 |
|
Description: Rabbit polyclonal Chymotrypsinogen B1 antibody raised against the middle region of CTRB1 |
|||
Chymotrypsinogen B1 antibody |
|||
| 70R-7531 | Fitzgerald | 50 ug | EUR 467 |
|
Description: Rabbit polyclonal Chymotrypsinogen B1 antibody raised against the N terminal of CTRB1 |
|||
 Carboxypeptidase B1 antibody |
|||
| 70R-5447 | Fitzgerald | 50 ug | EUR 467 |
|
Description: Rabbit polyclonal Carboxypeptidase B1 antibody |
|||
Cyclin B1 antibody |
|||
| 70R-5593 | Fitzgerald | 50 ug | EUR 467 |
|
Description: Rabbit polyclonal Cyclin B1 antibody raised against the middle region of CCNB1 |
|||
 Ephrin-B1 antibody |
|||
| 70R-6117 | Fitzgerald | 50 ug | EUR 467 |
|
Description: Rabbit polyclonal Ephrin-B1 antibody raised against the middle region of EFNB1 |
|||
 Cyclin B1 Antibody |
|||
| AF4708 | Affbiotech | 200ul | EUR 376 |
|
Description: Cyclin B1 Antibody detects endogenous levels of Cyclin B1. |
|||
Cyclin B1 Antibody |
|||
| AF6168 | Affbiotech | 200ul | EUR 304 |
|
Description: Cyclin B1 Antibody detects endogenous levels of total Cyclin B1. |
|||
Cyclin B1 Antibody |
|||
| AF6169 | Affbiotech | 200ul | EUR 304 |
|
Description: Cyclin B1 Antibody detects endogenous levels of total Cyclin B1. |
|||
 Lamin B1 Antibody |
|||
| BF1002 | Lifescience Market | 100 ug | EUR 469 |
Cyclin B1 Antibody |
|||
| ABF6168 | Lifescience Market | 100 ug | EUR 438 |
From 2006 to 2019, BB-BCH contained 252,069 samples from 44,933 contributors, the entire assortment is represented by 15 various kinds of biospecimens collected from them. According to our information, the most collected and saved topography in males is head and neck (29%); in girls is breast (28%); and in youngsters is torso and limb (27%) samples. Finally, we supported nationwide and worldwide consortia and initiatives equivalent to The Cancer Genome Atlas. BB-BCH is a crucial data supply for scientific group, enabling the growth of high-quality research, with all kinds of tumor classes and excessive nationwide representativeness of Brazilian inhabitants.